CTOs on the Move

Rain Carbon Inc.

www.raincarbon.com

 
Rain Carbon Inc. is the management and holding company for Rain CII and RÜTGERS, global leaders and innovators in the production of industrial chemicals.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Resource Corporation

Resource Corporation is a Toronto, ON-based company in the Business Services sector.

Kansas State University Foundation

The Kansas State University Foundation is a nonprofit organization dedicated to supporting Kansas State University (K-State) through philanthropy. Its mission is to inspire and guide charitable giving to enhance the universitys priorities, including funding scholarships, faculty positions, and campus infrastructure. The Foundation collaborates with university leaders, donors, and alumni to secure contributions that support K-States growth and mission. Key initiatives include the K-State Proud Student Campaign, which raises funds for Student Opportunity Awards, and the Student Foundation, which engages students in philanthropy. The Foundation also hosts the K-State Day of Giving, an annual event that encourages donations from the global K-State community. Other programs focus on improving classroom facilities and supporting families in scholarship giving. With around 181 employees and annual revenues of nearly $99.5 million, the Foundation is based in Manhattan, Kansas, and is recognized for its positive workplace culture and commitment to meaningful outcomes for the university community.

Image Exhibits

Image Exhibits is a Fort Wayne, IN-based company in the Business Services sector.

DRI Healthcare

DRI Healthcare is a pioneer in global pharmaceutical royalty monetization. Over the course of three decades, we have been a trusted partner of royalty sellers and demonstrated strong execution, building a diversified portfolio of interests in medicines that have a demonstrable positive impact on the world. That foundation sets us apart as we continue developing solutions for innovators while building and managing a risk-mitigated portfolio of therapeutic assets that generates attractive returns and growth potential for investors. We have deployed more than $2.5 billion, acquiring more than 70 royalties on 40-plus drugs.